USRE36320E - Method of increasing vaginal lubrication - Google Patents
Method of increasing vaginal lubrication Download PDFInfo
- Publication number
- USRE36320E USRE36320E US08/979,152 US97915297A USRE36320E US RE36320 E USRE36320 E US RE36320E US 97915297 A US97915297 A US 97915297A US RE36320 E USRE36320 E US RE36320E
- Authority
- US
- United States
- Prior art keywords
- hydriodic acid
- vaginal lubrication
- syrup
- increasing
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000005461 lubrication Methods 0.000 title claims abstract description 21
- 230000001965 increasing effect Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 12
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000006188 syrup Substances 0.000 claims abstract description 19
- 235000020357 syrup Nutrition 0.000 claims abstract description 19
- 210000000416 exudates and transudate Anatomy 0.000 claims description 8
- 210000001215 vagina Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 description 5
- 230000002509 aphrodisiac effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000036332 sexual response Effects 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 2
- 239000003048 aphrodisiac agent Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 230000036259 sexual stimuli Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001714 vasocongestive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
Definitions
- the normal sexual response begins with sexual arousal which causes genital vasocongestion that results in vaginal lubrication.
- the lubrication is due to the formation of a transudate in the vagina which, in conjunction with genital congestion, produces the so-called orgasmic platform prior to orgasm.
- sexual stimuli and healthy vaginal tissue are prerequisites for genital vasocongestion and vaginal lubrication, (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 12th ed., ed Wilson, J. D., et al. p. 301, McGraw-Hill Inc., New York (1991)).
- vaginal lubrication in response to sexual stimuli may decrease as a woman ages. Insufficient, or absence of, vaginal lubrication may result in unsatisfying, or painful sexual relations.
- Women experiencing stress may seek professional counseling by a therapist, physician or psychiatrist to overcome such problems and achieve normal sexual response.
- this option is often costly and time-consuming. Women suffering from a physical illness may be able to obtain relief through treatment of the underlying physical illness.
- This invention relates to a method of increasing, or stimulating vaginal lubrication in an adult human female by using hydriodic acid in an aqueous solution.
- the hydriodic acid is administered orally, as hydriodic syrup.
- the amount of transudate present in the vagina is increased, resulting in increased lubrication of the vagina.
- Oral administration of hydriodic acid to increase vaginal lubrication eliminates the problems associated with the application of creams and ointments to the vaginal area, thus simplifying preparation for sexual encounters and enhancing sexual satisfaction. Moreover, the risk of infection associated with external application of artificial lubricants is greatly reduced if not all together eliminated with the present invention.
- This invention is based upon the discovery that an aqueous solution of hydriodic acid can heighten sexual desire, including increasing the amount of transudate present in the vagina, resulting in increased vaginal lubrication.
- Hydriodic acid is a clear colorless, or pale yellow liquid, an aqueous solution of hydrogen iodide, which is a gas at ordinary temperature. Hydriodic acid is also known as anhydrous hydriodic acid, hydrogen iodide (HI), hydrogen monoiodide or hydriodic. (The Merck Index, Merck & Co.. Inc., 10th Ed. (1983)). Typically, hydriodic acid has been used as an expectorant, especially in the treatment of whooping cough (Pertussis).
- hydriodic acid of that, and the present, invention consists of hydriodic acid syrup comprised of hydriodic acid, water and dextrose. Hydriodic acid syrup was orally administered (ingested) to the subject. After approximately 24 hours, an aphrodisiac effect was experienced by the subject.
- aphrodisiac or "heightened sexual desire”, for the purposes of the present invention, refer to the following physical manifestations including clitoral swelling, nipple erection, contraction of the vaginal musculature, and a general tingling sensation.
- vaginal lubrication refers to an increased amount of transudate present in the vagina above the amount of transudate present in the vagina above the amount of transudate present in the unstimulated state.
- the method of increasing vaginal lubrication in a human female described herein comprises administering to a female in need of said treatment an effective amount of hydriodic acid syrup, comprising hydriodic acid, water and dextrose.
- an effective amount of hydriodic syrup for an adult human female weighing approximately 165 pounds is about 0.5 to 3.0 teaspoons of hydriodic acid syrup in 8 ounces of tap water. It is understood that higher or lower amounts of hydriodic acid syrup would be used for heavier or lighter subjects as in the purview of one skilled in the art.
- Hydriodic acid solution was purchased from Eli Lilly and Company, of Indianapolis, Ind., referred to as hydriodic acid syrup. Hydriodic acid syrup can also be prepared by combining hydriodic acid with purified water and dextrose. For example, 140 ml of hydriodic acid is mixed with 550 ml of purified water. To this mixture, 450 g of dextrose is added and dissolved by agitation. Quantity sufficient of purified water is then added to bring the volume to 1000 ml, and the solution is filtered.
- the syrup was administered orally to a female human, 52 years of age, weighing approximately 165 pounds. About 0.5 to 3.0 teaspoons of the hydriodic acid syrup was admixed with approximately 8 ounces of tap water and then ingested. An aphrodisiac effect, as defined above, including increased vaginal lubrication, was experienced within approximately 24 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of increasing vaginal lubrication comprising the use of hydriodic acid syrup. The hydriodic acid syrup is orally administered in the preferred embodiment.
Description
This application is a continuation-in-part of U.S. patent application Ser. No. 07/862,454, filed Apr. 2, 1992, now U.S. Pat No. 5,231,423, issued Jan. 25, 1994 the teachings of which are incorporated herein by reference.
The normal sexual response begins with sexual arousal which causes genital vasocongestion that results in vaginal lubrication. The lubrication is due to the formation of a transudate in the vagina which, in conjunction with genital congestion, produces the so-called orgasmic platform prior to orgasm. Sexual stimuli and healthy vaginal tissue are prerequisites for genital vasocongestion and vaginal lubrication, (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 12th ed., ed Wilson, J. D., et al. p. 301, McGraw-Hill Inc., New York (1991)).
Illnesses that impair neurological function, such as diabetes mellitus, may prevent normal sexual arousal. Pelvic diseases, such as vaginitis or endometriosis may also interfere with the normal sexual response. More commonly, decreased sexual response is due to psychological factors such as feelings of guilt, stresses such as anxiety, depression, fatigue or interpersonal conflicts which lead to failure of the vasocongestive response and prevent sufficient vaginal lubrication. (HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 12th ed., ed. Wilson, J. D., et al. p. 301, McGraw-Hill Inc., New York (1991)). In addition, vaginal lubrication in response to sexual stimuli may decrease as a woman ages. Insufficient, or absence of, vaginal lubrication may result in unsatisfying, or painful sexual relations.
Women experiencing stress may seek professional counseling by a therapist, physician or psychiatrist to overcome such problems and achieve normal sexual response. However, this option is often costly and time-consuming. Women suffering from a physical illness may be able to obtain relief through treatment of the underlying physical illness.
Alternatively, a number of creams or ointment preparations are commercially available for artificial lubrication. However, these preparation are often messy and inconvenient to use. Moreover, physical application of these artificial preparations are not always hygienic, and may introduce contaminants to the vaginal area, leading to irritation or infection. Thus, the need exists for a neat, hygienic, and convenient method of stimulating vaginal lubrication.
This invention relates to a method of increasing, or stimulating vaginal lubrication in an adult human female by using hydriodic acid in an aqueous solution. In the method of the present invention, the hydriodic acid is administered orally, as hydriodic syrup. Approximately 24 hours after oral administration, the amount of transudate present in the vagina is increased, resulting in increased lubrication of the vagina.
Oral administration of hydriodic acid to increase vaginal lubrication eliminates the problems associated with the application of creams and ointments to the vaginal area, thus simplifying preparation for sexual encounters and enhancing sexual satisfaction. Moreover, the risk of infection associated with external application of artificial lubricants is greatly reduced if not all together eliminated with the present invention.
This invention is based upon the discovery that an aqueous solution of hydriodic acid can heighten sexual desire, including increasing the amount of transudate present in the vagina, resulting in increased vaginal lubrication.
Hydriodic acid is a clear colorless, or pale yellow liquid, an aqueous solution of hydrogen iodide, which is a gas at ordinary temperature. Hydriodic acid is also known as anhydrous hydriodic acid, hydrogen iodide (HI), hydrogen monoiodide or hydriodic. (The Merck Index, Merck & Co.. Inc., 10th Ed. (1983)). Typically, hydriodic acid has been used as an expectorant, especially in the treatment of whooping cough (Pertussis).
As disclosed in the parent patent application, it has now been discovered that an aqueous solution of hydriodic acid has aphrodisiac properties, as confirmed through its use by an adult human female. The hydriodic acid of that, and the present, invention consists of hydriodic acid syrup comprised of hydriodic acid, water and dextrose. Hydriodic acid syrup was orally administered (ingested) to the subject. After approximately 24 hours, an aphrodisiac effect was experienced by the subject. The terms "aphrodisiac" or "heightened sexual desire", for the purposes of the present invention, refer to the following physical manifestations including clitoral swelling, nipple erection, contraction of the vaginal musculature, and a general tingling sensation.
Specifically, after oral administration of hydriodic acid syrup, the female subject experienced increased vaginal lubrication. The term "increased vaginal lubrication", as used herein, refers to an increased amount of transudate present in the vagina above the amount of transudate present in the vagina above the amount of transudate present in the unstimulated state.
Thus, the method of increasing vaginal lubrication in a human female described herein, comprises administering to a female in need of said treatment an effective amount of hydriodic acid syrup, comprising hydriodic acid, water and dextrose. As described in the Exemplification below, an effective amount of hydriodic syrup for an adult human female weighing approximately 165 pounds, is about 0.5 to 3.0 teaspoons of hydriodic acid syrup in 8 ounces of tap water. It is understood that higher or lower amounts of hydriodic acid syrup would be used for heavier or lighter subjects as in the purview of one skilled in the art. Thus, as a result of Applicant's discovery, a method is now provided for a neat, hygienic and convenient means of increasing vaginal lubrication in a human female.
The invention will be further illustrated by the following non-limiting Exemplification:
Exemplification
Hydriodic acid solution was purchased from Eli Lilly and Company, of Indianapolis, Ind., referred to as hydriodic acid syrup. Hydriodic acid syrup can also be prepared by combining hydriodic acid with purified water and dextrose. For example, 140 ml of hydriodic acid is mixed with 550 ml of purified water. To this mixture, 450 g of dextrose is added and dissolved by agitation. Quantity sufficient of purified water is then added to bring the volume to 1000 ml, and the solution is filtered.
The syrup was administered orally to a female human, 52 years of age, weighing approximately 165 pounds. About 0.5 to 3.0 teaspoons of the hydriodic acid syrup was admixed with approximately 8 ounces of tap water and then ingested. An aphrodisiac effect, as defined above, including increased vaginal lubrication, was experienced within approximately 24 hours.
Equivalents
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (4)
1. A method of increasing vaginal lubrication in an adult human female in need of said treatment, said treatment consisting essentially of increasing the amount of transudate present in the vagina, comprising orally administering to the female an effective amount of hydriodic acid syrup.
2. A method of claim 1 wherein the hydriodic acid syrup further comprises 140 ml of hydriodic acid, 550 ml of purified water and 450 g of dextrose.
3. A method of claim 1 wherein the effective amount of hydriodic acid syrup is approximately 0.5-3.0 teaspoons of hydriodic acid syrup.
4. A method of claim 3 wherein the effective amount of hydriodic acid syrup is added to approximately 8 ounces of water before administration. .Iadd.5. A method of increasing vaginal lubrication in an adult human female in need of said treatment, said treatment consisting essentially of increasing the amount of transudate present in the vagina, comprising orally administering to the female an effective amount of an aqueous solution of hydriodic acid. .Iaddend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/979,152 USRE36320E (en) | 1992-04-02 | 1997-11-26 | Method of increasing vaginal lubrication |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/862,454 US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
| US08/170,151 US5470588A (en) | 1992-04-02 | 1993-12-20 | Method of increasing vaginal lubrication |
| US08/979,152 USRE36320E (en) | 1992-04-02 | 1997-11-26 | Method of increasing vaginal lubrication |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/862,454 Continuation-In-Part US5281423A (en) | 1992-04-02 | 1992-04-02 | Use of hydriodic acid as an aphrodisiac |
| US08/170,151 Reissue US5470588A (en) | 1992-04-02 | 1993-12-20 | Method of increasing vaginal lubrication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE36320E true USRE36320E (en) | 1999-09-28 |
Family
ID=26865763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/979,152 Expired - Lifetime USRE36320E (en) | 1992-04-02 | 1997-11-26 | Method of increasing vaginal lubrication |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | USRE36320E (en) |
| AU (1) | AU672149B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5783254A (en) * | 1980-11-12 | 1982-05-25 | Nippon Nousan Kogyo Kk | Feed for animal |
| US4670256A (en) * | 1985-09-23 | 1987-06-02 | V. Valhalla Corp. | Vaginal conditioning for sexual activity |
-
1994
- 1994-12-19 AU AU81599/94A patent/AU672149B2/en not_active Expired
-
1997
- 1997-11-26 US US08/979,152 patent/USRE36320E/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5783254A (en) * | 1980-11-12 | 1982-05-25 | Nippon Nousan Kogyo Kk | Feed for animal |
| US4670256A (en) * | 1985-09-23 | 1987-06-02 | V. Valhalla Corp. | Vaginal conditioning for sexual activity |
Non-Patent Citations (14)
| Title |
|---|
| Buffam, J., "Pharmacosexology: The Effects of Drugs on Sexual Function, A Review," J. of Psychoactive Drugs, 14(1-2):5-44(1982). |
| Buffam, J., Pharmacosexology: The Effects of Drugs on Sexual Function, A Review, J. of Psychoactive Drugs, 14(1 2):5 44(1982). * |
| Carr, B.R. and Wilson, J.D. et al., "Disturbances of Menstruation and Sexual Function in Women" Harrionson's Principles of Internal Medicine, 12:299-301 (McGraw Hill Inc., New York) (1991). |
| Carr, B.R. and Wilson, J.D. et al., Disturbances of Menstruation and Sexual Function in Women Harrionson s Principles of Internal Medicine, 12:299 301 (McGraw Hill Inc., New York) (1991). * |
| McEvoy et al, AHFS, Drug Information pp. 1398 1399 (1987). * |
| McEvoy et al, AHFS, Drug Information pp. 1398-1399 (1987). |
| Nippon Nosan Kogyo (From Derwent Publications, Ltd., London, GB, Week 8226, May 25, 1982, Abstract No. AN 82 53897E and & JP A 57083254. * |
| Nippon Nosan Kogyo (From Derwent Publications, Ltd., London, GB, Week 8226, May 25, 1982, Abstract No. AN 82-53897E and JP-57083254). |
| Terapia Intr Medicamente et al., (From Derwent Publications. ltd., London, GB, Week 8834, Apr. 30, 1988, Abstract No. AN 88 240790 and & RO A 94261. * |
| Terapia Intr Medicamente et al., (From Derwent Publications. ltd., London, GB, Week 8834, Apr. 30, 1988, Abstract No. AN 88-240790 and RO-A94261). |
| The Merck Index, Tenth Edition, pp. 692 and 696 697 (1983). * |
| The Merck Index, Tenth Edition, pp. 692 and 696-697 (1983). |
| Waddell, T.G. and Ibach, D.M., "Modern Chemical Aphrodisiacs," Indian J. Pharm. Sci., 51(3): 79-82 (1989). |
| Waddell, T.G. and Ibach, D.M., Modern Chemical Aphrodisiacs, Indian J. Pharm. Sci., 51(3): 79 82 (1989). * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU8159994A (en) | 1995-02-16 |
| AU672149B2 (en) | 1996-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Richardson | SIMMONDS'DISEASE AND ANOREXIA NERVOSA | |
| JP2001513552A (en) | Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome | |
| Jefferies | Safe uses of cortisol | |
| MXPA03006411A (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence. | |
| US5470588A (en) | Method of increasing vaginal lubrication | |
| USRE36320E (en) | Method of increasing vaginal lubrication | |
| US20030108621A1 (en) | Use of iodide salt as an aphrodisiac | |
| Bending | Recurrent bilateral reversible migrainous hemiparesis during pregnancy | |
| Parfitt | Psychoses associated with childbirth | |
| Laskiewicz | Changes in the upper respiratory organs and the ear on the underlying disfunction of the thyroid gland (hypothyreosis) | |
| TS et al. | N913 $‘P00nfu| of | |
| Drew et al. | Chemical Encephalomyelopathy: Report of a Case | |
| Cohen | Sex after sixty | |
| US20040127512A1 (en) | Method of treating symptoms of non-constipated irritable bowel syndrome | |
| Ford | R au Wil oi d® | |
| Tedstrom et al. | Menstrual Hypoglycemia and Functional Dysmenorrhea: Their Relationship | |
| Wechsler | The Psychoneuroses and Internal Secretions | |
| US4382095A (en) | Pharmaceutical methods and compositions using parabenzoquinone | |
| US4522830A (en) | Pharmaceutical methods using parabenzoquinone to treat muscle spasms | |
| Burstein et al. | Severe Hypotensive Reaction to Oral Chlorpromazine Therapy | |
| TABLETS | Ouixalin | |
| FORM | Megaoilli'* B22% § % m | |
| El Personal Pension et al. | The Insurance Society that belongs to the Medical and Dental professions | |
| Hanson | Myasthenia gravis: Case report and analysis | |
| EGNAVITIE | SAIFIER PREGNANCY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: RAINBURST, LLC, DISTRICT OF COLUMBIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REILLY, SUSANN;REEL/FRAME:009958/0705 Effective date: 19990113 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| SULP | Surcharge for late payment | ||
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| SULP | Surcharge for late payment |
Year of fee payment: 11 |